BioVentrix has enrolled the first patient in the US arm of the ALIVE pivotal clinical trial of the Revivent TC TransCatheter Ventricular Enhancement System to treat patients suffering from heart failure (HF) symptoms related to cardiomyopathy.

The trial is designed to demonstrate the safety and effectiveness of the Revivent TC, which uses a hybrid closed-chest procedure to treat patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company has also secured investigational device exemption (IDE) approval for the trial from the US Food and Drug Administration (FDA).

Interventional cardiologist Dr Catalin Toma and cardiothoracic surgeon Dr Christopher Sciortino have carried out the Less Invasive Ventricular Enhancement (LIVE) procedure at the UPMC Heart and Vascular Institute.

During the procedure, the device was successfully implanted with three micro-anchor pairs in a 42-year-old female patient suffering from ischemic heart failure.

“The procedure aims to reshape the left ventricle, decrease the left ventricular end systolic volume index (LVESVI), and increase the ejection fraction (EF).”

Toma said: “UPMC remains at the forefront of implementing promising less invasive therapies to address the need for better heart failure treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are pleased to be the first US centre to implant the Revivent TC System as part of the ALIVE clinical trial.

“The procedure aims to reshape the left ventricle, decrease the left ventricular end systolic volume index (LVESVI), and increase the ejection fraction (EF). The patient was discharged shortly after the procedure and is recovering well.”

A total of 120 patients are planned to be enrolled in the ALIVE trial at up to 20 sites in the US and the UK with a primary endpoint analysis at one year.

The endpoints of the trial include positive effects on volume reduction, ejection fraction, quality of life (QOL), New York Heart Association (NYHA) Class, a six-minute walk test, and rehospitalisation.